Indoco Remedies Ltd. News and Updates

Name: Latest research reports of Indoco Remedies Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Indoco Remedies Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Indoco Remedies Ltd. from all sources in a single place.

Load latest

Indoco Remedies Ltd.

30 Dec 2020

317.15

-1.44%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Securities Limited

H1 growth was led by strong growth in export markets (albeit on lower base), strong gross margins and lower travel & promotional spends. The management has guided for significant export growth and margin improvement for FY21. After going through rough patches in FY18-19, where Indoco faced headwinds on the domestic front (structural issues) and exports front (regulatory setbacks), the situation is returning to normalcy. While FY21 growth in the domestic market is likely to be subdued due to Covid-19, exports are likely to deliver robust growth on the back of strong...

Indoco Remedies Ltd. average weekly volume is high.

Indoco Remedies Ltd.

08 Dec 2020

317.15

-1.44%

Indoco Remedies share price falls nearly 7% despite tender win in Germany

Moneycontrol

The share is trading 4.45 percent below its 52-week high and 104.58 percent above its 52-week low.

Indoco Remedies Ltd. is trading above all available SMAs

Indoco Remedies Ltd.

03 Dec 2020

317.15

-1.44%

Indoco Remedies share price hits 52-week high after Dovetail India Fund buys 5 lakh shares

Moneycontrol

Dovetail India Fund purchased 5 lakh equity shares resulting in 0.58 percent stake at Rs 265.31 per share, data available on BSE showed. However, OHM Juniper Longterm Fund offloaded 0.54 percent stake in the company at a share price of Rs 265.31 per share.

Indoco Remedies Ltd. average weekly volume is high.

Matrimony.com rallies 10% after block deals; stock hits fresh 52-week high

Business Standard | 03 Dec 2020 1 more

Indoco Remedies Ltd.

12 Nov 2020

317.15

-1.44%

Buy Indoco Remedies; target of Rs 352: Prabhudas Lilladher

Moneycontrol

Prabhudas Lilladher is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 352 in its research report dated November 09, 2020.

Indoco Remedies Ltd. has gained 32.78% in the last 3 Months

Indoco Remedies Ltd.

28 Sep 2020

317.15

-1.44%

Indoco Remedies climbs 5 per cent Favipiravir tablets launch for Covid

Business Line

Shares of Indoco Remedies climbed nearly 5 per cent reacting positively to the reports that the pharma company has launched Favipiravir tablets used i

Indoco Remedies Ltd. has an average target of 320.00 from 2 brokers.

Indoco Remedies rallies 9% after launching Covid treatment drug

Business Standard | 28 Sep 2020

Indoco Remedies Ltd.

16 Sep 2020

317.15

-1.44%

Indoco Remedies surges 28% in 4 days post USFDA nod for Apixaban tablets

Business Standard

As per IMS MAT June'20 data, the US market size of Apixaban tablets is $11,037 million.

Indoco Remedies Ltd. average weekly volume is high.

Indoco Remedies Ltd.

14 Sep 2020

317.15

-1.44%

Indoco Remedies soars 19% on US FDA approval for Apixaban tablets

Business Standard

Apixaban is an anticoagulant, or blood thinner, used for patients with health problems caused by a blood clot

Indoco Remedies Ltd. average weekly volume is high.

Indoco Remedies gets USFDA nod for blood thinning drug Apixaban tablets

Business Standard | 14 Sep 2020

Indoco Remedies Ltd.

17 Aug 2020

317.15

-1.44%